SAN DIEGO, CA, Oct. 2 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation announced today that Gregory M. McKee, the Company’s President and Chief Executive Officer, will present at two upcoming investor conferences:
www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NVN.TO&item_id=1660569
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation and access to the BIO Investor Forum webcast, please visit the Company’s website located at www.nventacorp.com.
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive, Suite 180, San Diego, CA USA 92121, Tel: (858) 202-4945, Fax: (858) 450-6849, dslade@nventacorp.com
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive,
Suite 180, San Diego, CA USA 92121, Tel: (858) 202-4945, Fax: (858)
450-6849, dslade@nventacorp.com
